<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03054168</url>
  </required_header>
  <id_info>
    <org_study_id>Hormones</org_study_id>
    <nct_id>NCT03054168</nct_id>
  </id_info>
  <brief_title>Systemic Hormones and Muscle Protein Synthesis</brief_title>
  <official_title>The Regulation of Skeletal Muscle Protein Synthesis by Systemic Hormones and Its Influence on Ageing and Anabolic Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nottingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nottingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of increase in testosterone levels in older males and the&#xD;
      effects of decrease in testosterone levels in young males on muscle protein synthesis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Skeletal muscle represents the largest organ in the body, comprising &gt;50% of total body mass.&#xD;
      The function of skeletal muscle is best understood for its role in locomotion and providing&#xD;
      mechanical support to the skeleton to facilitate movement. However, skeletal muscles are also&#xD;
      important for maintaining whole-body metabolic health. For example, muscles also act as a&#xD;
      site for glucose disposal thereby acting to maintain whole-body glycaemic control. In&#xD;
      addition, skeletal muscles represent a vast protein store, the amino acids from which can be&#xD;
      used in times of fasting, infection and disease to provide energy to maintain other critical&#xD;
      organs. Exercise (resistance type exercise (RE-T) in particular) still remains the most&#xD;
      effective means by which to maintain and increase muscle mass through stimulation of muscle&#xD;
      protein synthesis (MPS), despite this, how exercise regulates these changes in muscle mass is&#xD;
      still unknown. A number of pathways have been inferred as key, however it is clear from a&#xD;
      number of studies that systemic hormone levels, testosterone in particular, may provide a&#xD;
      significant contribution. It is well known that chronic androgenic hormone deficiency can&#xD;
      lead to a loss of lean body mass and strength, which can in turn contribute to impaired&#xD;
      physical function. Furthermore, when testosterone levels are pharmacologically reduced (using&#xD;
      a gonadotropin releasing hormone analogue) in healthy young males, resistance exercise&#xD;
      training induced increases in muscle mass and strength are absent. Whilst systemic hormone&#xD;
      levels are carefully maintained in youth (unless illness or deficiency is present), levels of&#xD;
      these hormones decrease with age, particularly in those that are not regularly physically&#xD;
      active, indeed approximately 25-30% of older men have levels of testosterone which are below&#xD;
      the threshold used to define hypogonadism. Therefore, there is significant need to understand&#xD;
      the underlying mechanisms behind hormonally induced muscle mass regulation. Furthermore, in&#xD;
      older age there is a resistance to traditional anabolic stimuli such as nutrition or&#xD;
      resistance exercise, with older adults showing a blunted-anabolic hormonal profile in&#xD;
      response to resistance training compared to young. These impairments to hormonal regulation&#xD;
      with ageing may in part be responsible for the slow decline in muscle mass with age known as&#xD;
      sarcopenia. Whilst all muscle-wasting conditions are of considerable concern, it is the loss&#xD;
      of muscle in older age that poses the greatest socio-economic burden. Therefore there is a&#xD;
      significant clinical need to identify contributing factors to this muscle loss so that they&#xD;
      can be specifically targeted for intervention (i.e., pharmacological hormonal therapies).&#xD;
&#xD;
      The aims of this project are two fold: 1) Firstly we aim to investigate the impact of&#xD;
      systemic hormone levels on control of muscle mass in healthy young adults undertaking a&#xD;
      resistance exercise training program, we hypothesize that reduction of hormone levels in&#xD;
      systemically normal young adults will impair MPS and muscle mass gains in response to&#xD;
      resistance exercise training. 2) Secondly we aim to investigate the impact of enhancing&#xD;
      testosterone levels in older adults on responsiveness to resistance exercise training and the&#xD;
      contribution of systemic testosterone levels to muscle mass regulation in ageing, we&#xD;
      hypothesize that increasing testosterone levels in older males will improve responsiveness to&#xD;
      anabolic stimuli (RE-T).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">December 15, 2016</start_date>
  <completion_date type="Anticipated">February 15, 2019</completion_date>
  <primary_completion_date type="Actual">November 15, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>To achieve our aims we will recruit 16 young healthy males (Age: 18-30 y; BMI: 18-30kg/m2) and 16 older healthy males (Age: 65-75 y; BMI: 18-30kg/m2). Volunteers will then be randomly assigned to a testing group; 1) Young placebo trained (N=10), 2) Young gonadotropin releasing hormone analogue trained (3.6mg Zoladex subcutaneous injection (every 4 weeks) N=10), 3) Old placebo trained (N=10) and 4) Old Testosterone trained (Sustanon 250: 250 mg every 2-3wks intramuscular injection, N=10). All participants will receive whole body resistance exercise training for six weeks.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle Protein Synthesis</measure>
    <time_frame>0-6 Weeks</time_frame>
    <description>Comparison of muscle protein synthesis between young and older individuals when their testosterone levels decrease and increase, respectively; in response to 6 weeks whole body resistance exercise training</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Sarcopenia</condition>
  <condition>Muscle Hypotrophy</condition>
  <condition>Muscle Atrophy</condition>
  <arm_group>
    <arm_group_label>Old Testosterone trained</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 old participants (65-75 years old) who will receive resistance exercise training and Testosterone (Sustanon 250: 250 mg every 2wks)&#xD;
Drug name: Sustanon 250 Generic Name: Testosterone Proprietary Name: N/A Formulation: 250mg of Testosterone in 1ml volume Dose: 250mg of testosterone Frequency: every 2 weeks Route: intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Old Placebo trained</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>8 old participants (65-75 years old) who will receive resistance exercise training and Placebo every two weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Young Zoladex trained</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 young participants (18-30 years old) who will receive resistance exercise training and Testosterone inhibitor (3.6mg Zoladex subcutaneous injection, one time over the study)&#xD;
Drug name: Zoladex Generic Name: Gonadotropin-releasing hormone analogue; Goserelin Proprietary Name: N/A Formulation: Solution for injection Dose: 3.6mg Frequency: Single injection one time over the study. Route: Subcutaneous injection (abdomen) performed by clinician.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Young placebo trained</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>8 young participants (18-30 years old) who will receive resistance exercise training and placebo, one time over the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sustanon 250</intervention_name>
    <description>The frequency of the injection will be every 2 weeks, 250mg of testosterone, intramuscular injection.</description>
    <arm_group_label>Old Testosterone trained</arm_group_label>
    <other_name>Testosterone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoladex</intervention_name>
    <description>The frequency of the injection will be just one injection, 3.6 mg of Zoladex, Subcutaneous injection (abdomen).</description>
    <arm_group_label>Young Zoladex trained</arm_group_label>
    <other_name>Gonadotropin-releasing hormone analogue; Goserelin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Old Placebo trained</arm_group_label>
    <arm_group_label>Young placebo trained</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Young (18-30y) and old (60-75y) males who are generally healthy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in a formal exercise regime&#xD;
&#xD;
          -  BMI &lt; 18 or &gt; 30 kgÂ·m2&#xD;
&#xD;
          -  Active cardiovascular disease:&#xD;
&#xD;
               -  uncontrolled hypertension (BP &gt; 160/100),&#xD;
&#xD;
               -  angina,&#xD;
&#xD;
               -  heart failure (class III/IV),&#xD;
&#xD;
               -  arrhythmia,&#xD;
&#xD;
               -  right to left cardiac shunt,&#xD;
&#xD;
               -  recent cardiac event&#xD;
&#xD;
          -  Taking beta-adrenergic blocking agents, statins, non-steroidal anti-inflammatory drugs&#xD;
             or HRT&#xD;
&#xD;
          -  Cerebrovascular disease:&#xD;
&#xD;
               -  previous stroke,&#xD;
&#xD;
               -  aneurysm (large vessel or intracranial)&#xD;
&#xD;
               -  epilepsy&#xD;
&#xD;
          -  Respiratory disease including:&#xD;
&#xD;
               -  pulmonary hypertension,&#xD;
&#xD;
               -  COPD,&#xD;
&#xD;
               -  asthma,&#xD;
&#xD;
          -  Metabolic disease:&#xD;
&#xD;
               -  hyper and hypo parathyroidism,&#xD;
&#xD;
               -  Hypo and hyper gonadism&#xD;
&#xD;
               -  untreated hyper and hypothyroidism,&#xD;
&#xD;
               -  Cushing's disease,&#xD;
&#xD;
               -  type 1 or 2 diabetes&#xD;
&#xD;
          -  Active inflammatory bowel or renal disease&#xD;
&#xD;
          -  Malignancy&#xD;
&#xD;
          -  Altered hormonal profile&#xD;
&#xD;
          -  Recent steroid treatment (within 6 months) or hormone replacement therapy&#xD;
&#xD;
          -  Clotting dysfunction&#xD;
&#xD;
          -  Musculoskeletal or neurological disorders&#xD;
&#xD;
          -  Family history of early (&lt;55y) death from cardiovascular disease&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>All participants are male.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip J Atherton, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Nottingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nathaniel Szewczyk, Ass. Proff</last_name>
    <role>Study Chair</role>
    <affiliation>The University of Nottingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Derby Hospital Medical School</name>
      <address>
        <city>Derby</city>
        <state>Derbyshire</state>
        <zip>DE22 3DT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Mauras N, Hayes V, Welch S, Rini A, Helgeson K, Dokler M, Veldhuis JD, Urban RJ. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab. 1998 Jun;83(6):1886-92.</citation>
    <PMID>9626114</PMID>
  </reference>
  <reference>
    <citation>Kvorning T, Andersen M, Brixen K, Madsen K. Suppression of endogenous testosterone production attenuates the response to strength training: a randomized, placebo-controlled, and blinded intervention study. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1325-32. Epub 2006 Jul 25.</citation>
    <PMID>16868226</PMID>
  </reference>
  <reference>
    <citation>Abbasi AA, Drinka PJ, Mattson DE, Rudman D. Low circulating levels of insulin-like growth factors and testosterone in chronically institutionalized elderly men. J Am Geriatr Soc. 1993 Sep;41(9):975-82.</citation>
    <PMID>8409184</PMID>
  </reference>
  <reference>
    <citation>Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR; Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001 Feb;86(2):724-31.</citation>
    <PMID>11158037</PMID>
  </reference>
  <reference>
    <citation>Baker JR, Bemben MG, Anderson MA, Bemben DA. Effects of age on testosterone responses to resistance exercise and musculoskeletal variables in men. J Strength Cond Res. 2006 Nov;20(4):874-81.</citation>
    <PMID>17194250</PMID>
  </reference>
  <reference>
    <citation>Kumar V, Selby A, Rankin D, Patel R, Atherton P, Hildebrandt W, Williams J, Smith K, Seynnes O, Hiscock N, Rennie MJ. Age-related differences in the dose-response relationship of muscle protein synthesis to resistance exercise in young and old men. J Physiol. 2009 Jan 15;587(1):211-7. doi: 10.1113/jphysiol.2008.164483. Epub 2008 Nov 10.</citation>
    <PMID>19001042</PMID>
  </reference>
  <reference>
    <citation>Vingren JL, Kraemer WJ, Ratamess NA, Anderson JM, Volek JS, Maresh CM. Testosterone physiology in resistance exercise and training: the up-stream regulatory elements. Sports Med. 2010 Dec 1;40(12):1037-53. doi: 10.2165/11536910-000000000-00000. Review.</citation>
    <PMID>21058750</PMID>
  </reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 10, 2017</study_first_submitted>
  <study_first_submitted_qc>February 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2017</study_first_posted>
  <last_update_submitted>February 22, 2019</last_update_submitted>
  <last_update_submitted_qc>February 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nottingham</investigator_affiliation>
    <investigator_full_name>Philip Atherton</investigator_full_name>
    <investigator_title>Philip Atherton</investigator_title>
  </responsible_party>
  <keyword>Protein Synthesis</keyword>
  <keyword>Hypertrophy</keyword>
  <keyword>Testosterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Testosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

